Study on Bioequivalence of Sodium Valproic Sustained-Release Compound Tablets in Healthy Volunteers
CUI Yi-min,SUN Pei-Hong,LIU Yu-Wang,ZHAO Xia,LI Rong,SUN Zhong-min
(Peking University First Medical School, Beijing 100034)
Abstract OBJECTIVE: To evaluate relative bioavailability of domestic and imported sodium valproic sustained-release compound tablets in healthy volunteers. METHODS: A single and a multi oral administration of 500mg domestic and imported sodium valproic sustained-release compound tablets were given to two group 20 healthy male volunteers in randomized crossover study respectively. A high performance liquid chromatographic assay with fluorimetric detection was developed to determine the concentration of sodium valproic in human serum. The data were analyzed by 3P97 program. RESULTS: The pharmacokinetics parameters after a single oral administration of 500mg domestic and imported products were as follows: Cmax 36.45±6.57 and 34.40±4.66 mg·L-1; Tmax 11.20±1.60 and 10.20±2.75h; AUC0-∞ 1329.87±397.49 and 1243.43±360.00mg.L-1.h, 108.38±19.95% respectively. The pharmacokinetics parameters after a multi oral administration of 500mg domestic and imported products were as follows: Cmax 59.05±10.67 and 60.69±14.81 mg.L-1; Cmin 38.17±9.36 and 35.48±9.44 mg.L-1; Tmax 8.80±3.43 and 7.75±3.16h; DF% 44.95±15.48% and 53.99±17.41%; AUCss0-t 1154.94±237.05 and 1142.82±293.71mg.L-1.h respectively. Variance analysis and two one-sided test were performed to parameters: Cmax, AUC0-∞ of single oral administration group and parameters: Cmax, AUCss0-t of multi oral administration group. There were no significant difference. CONCLUSION: The two preparations were of bioequivalence, the relative bioavailabilities of single oral administration group and multi oral administration group were 108.38±19.95% and 105.42±24.36% respectively.
Key words sodium valproic; bioavailability; pharmacokinetics; bioequivalence
丙戊酸钠(sodium valproic)是一种广谱抗癫痫药,目前临床应用剂型主要为普通片剂、缓释片和糖浆剂。本文采用高效液相色谱-荧光检测法测定了单次和多次口服国产复方丙戊酸钠缓释片和进口复方丙戊酸钠缓释片后的血药浓度,计算有关药代动力学参数和相对生物利用度,并对两制剂的生物等效性进行了评价。本课题的“申请药物临床试验报告”获得北京医科大学“临床药理研究中心”及“药物临床试验道德委员会”的批准。
材 料 与 方 法
1. 药品与试剂
试验药品:国产复方丙戊酸钠缓释片:杭州赛诺菲民生制药有限公司生产,每片500mg,批号:T-9904。
对照药品:进口分装复方丙戊酸钠缓释片剂(商品名:德巴金(缓释片):赛诺菲-温莎(英国)制药有限公司生产,杭州赛诺菲民生制药有限公司分装,每片500mg,批号:9909025。
丙戊酸钠标准品:丙戊酸钠含量99.5%,由赛诺菲-温莎(英国)制药有限公司提供。
试剂:甲醇、乙腈(色谱纯),Fisher Scientific (Hong Kong ) Ltd.;三乙胺(分析纯),日本进口分装,中国医药公司北京采购供应站经销;1,2-丙二醇(分析纯),北京化学试剂公司;盐酸(分析纯),北京化工厂;庚酸(色谱纯),上海星火化工厂;4-溴甲基-6,7-二甲氧基香豆素(BrDMC)为SIGMA产品;乙醚为重蒸乙醚;水为重蒸馏去离子水。
Fig1.Chromatograms ofsodiumvalproicand internal standard
A:Blank human serum; B:Blank human serumspiked with sodium valproic
and internal standard;C:Human serumcollected froma volunteer 1 h
after a single oral dose of sodium valproic sustained release compound
tablet(500mg).Peak 1: internal standard;Peak 2:sodium valproic.
Fig2. Mean serum concentration-time curves ofsodium valproicafter a
single oral dose of500mg in 20 healthy male volunteers
Fig3. Mean serum concentration-time curves ofsodium valproicafter a
multioraldose of500mg in 20 healthy male volunteers
2. 仪器和色谱条件
SHIMADZU LC-9A高效液相色谱系统:LC-9A 泵;RF-535荧光检测器;SCL-6B中心控制器;C-R6A积分仪;CTO-6A柱温箱;ZORBAX 5mm ODS 250mm×4.6mm色谱柱。流动相为乙腈:水(65:35, v/v);流速:1.2 ml/min,检测波长:激发波长325nm,发射波长398nm;进样量:20ml。
3. 标准曲线与方法考察
线性范围:于健康人空白血清中加入不同量的丙戊酸钠标准溶液,使其浓度分别为1,2,5,10,25,50,75,100mg·L-1,按血样处理方法萃取测定。血清中丙戊酸钠的浓度按检测药物的色谱峰面积计算,以药物浓度C对药物色谱峰面积As/内标色谱峰面积Ai进行线性回归。
精密度和回收率:在空白血清中加入不同量的丙戊酸钠标准溶液,配制成低、中、高(5,25,75mg·L-1)三个浓度的血清样品,按前法分别于日内和日间提取,测定日内、日间变异并考察其方法回收率。
4. 健康志愿者的选择与给药方案
健康志愿者的选择:40名健康男性志愿者均为北京医科大学在校学生。单次给药组20人平均年龄为21.10±2.00岁,平均身高为1.71±0.05m,平均体重为67.30±7.24kg,。多次给药组20人平均年龄为22.10±1.74岁,平均身高为1.75±0.07m,平均体重为66.35±6.85kg。受试者经心电图、血压、血尿常规、肝、肾功能检查均为正常。40名受试者均无吸烟、饮酒史,受试前两周未服用过任何药物。各受试者均自愿参加试验并在试验前由本人签署知情同意书。
给药方案:本试验采用两周期随机交叉试验设计。单次给药组20名受试者于试验前一天吃清淡晚餐后禁食12h,受试当天早晨空腹用250ml温水送服国产或进口复方丙戊酸钠缓释片500mg,两周后交叉服用另一制剂。分别于服药前及服药后1,2,3,4,6,8,10,12,14,24,36,48及72h取静脉血2ml;多次口服给药组20名受试者分别于每日晨7:30口服国产或进口复方丙戊酸钠缓释片500mg,连续服用3日后于第四、五、六日晨7:30服药前取血测定稳态谷浓度,证明达稳态后于第六日吃清淡晚餐后禁食12h,第七日晨7:30空腹用250ml温水送服国产或<
